AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28769121 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise
Number of subjects: 47
Study 28769121 — intervention group
Group type: COMPARATOR
Intervention: Control (resting throughout the trial)
Number of subjects: 47
Study 26192383 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed message emphasizing benefits of avoiding IT
Number of subjects: 475
Study 26192383 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed message emphasizing risks of IT
Number of subjects: 475
Study 26192383 — intervention group
Group type: COMPARATOR
Intervention: Self-affirmation manipulation
Number of subjects: 475
Study 26192383 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no self-affirmation)
Number of subjects: 475
Study 24715380 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment
Number of subjects: 912
Study 24715380 — intervention group
Group type: COMPARATOR
Intervention: No endocrine treatment
Number of subjects: 912
Study 22040311 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% saline in 5% dextrose (hypotonic fluid group)
Number of subjects: 84
Study 22040311 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline in 5% dextrose (isotonic fluid group)
Number of subjects: 84
Study 22040311 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 84
Study 19630998 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture closure of the pancreatic remnant
Number of subjects: 23
Study 17582159 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 137
Study 17582159 — intervention group
Group type: COMPARATOR
Intervention: Intravenous methylprednisolone
Number of subjects: 137
Study 16422961 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernous injection of 1 mL bimix (30 mg papaverine + 1 mg phentolamine) followed by 1 mL mixture of papaverine and chlorpromazine (30 mg papaverine + 2.5 mg chlorpromazine)
Number of subjects: 50
Study 16422961 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernous injection of 1 mL trimix (30 mg papaverine + 1 mg phentolamine + 10 microg PGE1) followed by 1 mL mixture of papaverine, PGE1, and chlorpromazine (30 mg papaverine + 2.5 mg chlorpromazine + 10 microg PGE1)
Number of subjects: 50
Study 16422961 — intervention group
Group type: EXPERIMENTAL
Intervention: Various intracavernous injections of chlorpromazine in doses 1 mg, 2 mg, 5 mg, and 10 mg
Number of subjects: 50
Study 11883914 — intervention group
Group type: EXPERIMENTAL
Intervention: Chocolate condition (CC, N=13)
Number of subjects: 82
Study 11883914 — intervention group
Group type: EXPERIMENTAL
Intervention: Bread and butter condition (BC, N=16)
Number of subjects: 82
Study 11883914 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed chocolate condition (FS, N=20)
Number of subjects: 82
Study 11883914 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable chocolate condition (VS, N=18)
Number of subjects: 82
Study 11883914 — intervention group
Group type: COMPARATOR
Intervention: Control condition (CS, N=15)
Number of subjects: 82
Study 9652303 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen challenge in food-sensitized children
Number of subjects: 26
Study 9652303 — intervention group
Group type: COMPARATOR
Intervention: Placebo challenge in sensitized patients
Number of subjects: 26
Study 9652303 — intervention group
Group type: COMPARATOR
Intervention: Placebo challenge in non-sensitized group
Number of subjects: 26
Study 8590553 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate infusion
Number of subjects: 0
Study 8590553 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenergic receptor blockade (propranolol)
Number of subjects: 0
Study 8590553 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate infusion with propranolol
Number of subjects: 0
Study 8590553 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 0
Study 2498781 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 0.5 mg i.v. in 15 min (Group A)
Number of subjects: 44
Study 2498781 — intervention group
Group type: COMPARATOR
Intervention: Glucose 40 g i.v. plus 10 units insulin i.v. in 15 min (Group B)
Number of subjects: 44
Study 2498781 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 0.5 mg i.v., glucose 40 g i.v. and insulin 10 units i.v. over 15 min (Group C)
Number of subjects: 44
Study 367714 — intervention group
Group type: COMPARATOR
Intervention: Levodopa alone
Number of subjects: 21
Study 367714 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa and carbidopa (Sinemet)
Number of subjects: 21
Study 31212041 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaced instruction (four weekly sessions)
Number of subjects: 48
Study 31212041 — intervention group
Group type: COMPARATOR
Intervention: Massed instruction (two sequential days)
Number of subjects: 48
Study 29165168 — intervention group
Group type: EXPERIMENTAL
Intervention: Winter sample (154 students)
Number of subjects: 301
Study 29165168 — intervention group
Group type: EXPERIMENTAL
Intervention: Spring sample (147 students)
Number of subjects: 301
Study 25384419 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management Acceptance and Commitment Therapy-based training intervention (ACTr)
Number of subjects: 100
Study 25384419 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge- and skills-based Dialectical Behaviour Training intervention (DBTr)
Number of subjects: 100
Study 23511362 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 42
Study 23511362 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 42
Study 21804337 — intervention group
Group type: EXPERIMENTAL
Intervention: Laughter therapy (8 sessions, twice a week for 60 minutes each)
Number of subjects: 37
Study 21804337 — intervention group
Group type: COMPARATOR
Intervention: Control group (no laughter therapy)
Number of subjects: 37
Study 18998161 — intervention group
Group type: EXPERIMENTAL
Intervention: Accuracy instructions
Number of subjects: 0
Study 18998161 — intervention group
Group type: COMPARATOR
Intervention: Implicit learning processes
Number of subjects: 0
Study 18163861 — intervention group
Group type: EXPERIMENTAL
Intervention: Claims-based audit and feedback
Number of subjects: 0
Study 18163861 — intervention group
Group type: EXPERIMENTAL
Intervention: Claims- and medical-record-based audit and feedback
Number of subjects: 0
Study 18163861 — intervention group
Group type: EXPERIMENTAL
Intervention: Claims- and medical-record-based audit and feedback plus a practice-based diabetes resource nurse
Number of subjects: 0
Study 14969665 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal contraceptive system (Ortho Evra)
Number of subjects: 3319
Study 14969665 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptive (OC)
Number of subjects: 3319
Study 14969665 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal contraceptive system (Ortho Evra) and Oral contraceptive (OC)
Number of subjects: 3319
Study 12475842 — intervention group
Group type: EXPERIMENTAL
Intervention: INS316 (10 to 180 mg)
Number of subjects: 26
Study 12475842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 9649975 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 44
Study 9649975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 9649975 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (in severe depression subsample)
Number of subjects: 44
Study 8023691 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental Bonding Instrument (PBI) assessment
Number of subjects: 4
Study 8023691 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental Bonding Instrument (PBI) - affectionless control quadrant assignment
Number of subjects: 4
Study 2589361 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous/oral ciprofloxacin
Number of subjects: 71
Study 2589361 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 71
Study 2589361 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin
Number of subjects: 71
Study 31902690 — intervention group
Group type: EXPERIMENTAL
Intervention: High Fidelity (HF) simulation model
Number of subjects: 36
Study 31902690 — intervention group
Group type: COMPARATOR
Intervention: Low Fidelity (LF) simulation model
Number of subjects: 36
Study 29504059 — intervention group
Group type: EXPERIMENTAL
Intervention: Brisk walking program (3 sessions of 60 min per week for 6 months)
Number of subjects: 94
Study 29504059 — intervention group
Group type: COMPARATOR
Intervention: Brisk walking program
Number of subjects: 94
Study 27281879 — intervention group
Group type: EXPERIMENTAL
Intervention: PHC Cage (polyaminoacid/nano-hydroxyapatite/calcium sulfate)
Number of subjects: 30
Study 27281879 — intervention group
Group type: COMPARATOR
Intervention: PEEK Cage
Number of subjects: 30
Study 25529410 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation (ES) following Botulinum Toxin A (BoNT/A) injection
Number of subjects: 6
Study 25529410 — intervention group
Group type: COMPARATOR
Intervention: Control (only daily stretch)
Number of subjects: 6
Study 23249876 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 2633
Study 23249876 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 2633
Study 20516300 — intervention group
Group type: EXPERIMENTAL
Intervention: Round-ended bur
Number of subjects: 50
Study 20516300 — intervention group
Group type: COMPARATOR
Intervention: Torpedo-shaped bur
Number of subjects: 50
Study 19134273 — intervention group
Group type: EXPERIMENTAL
Intervention: Excel (bioabsorbable polymer sirolimus-eluting stent)
Number of subjects: 591
Study 19134273 — intervention group
Group type: COMPARATOR
Intervention: Cypher (durable polymer sirolimus-eluting stent)
Number of subjects: 591
Study 16155038 — intervention group
Group type: EXPERIMENTAL
Intervention: Oesophageal Doppler guided fluid management
Number of subjects: 128
Study 16155038 — intervention group
Group type: COMPARATOR
Intervention: Central venous pressure (CVP)‐based fluid management
Number of subjects: 128
Study 14768494 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective beta-blockers
Number of subjects: 0
Study 14768494 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 10573659 — intervention group
Group type: COMPARATOR
Intervention: Creatine (Cr)
Number of subjects: 16
Study 10573659 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 16
Study 10162149 — intervention group
Group type: EXPERIMENTAL
Intervention: VA hospital care
Number of subjects: 0
Study 10162149 — intervention group
Group type: COMPARATOR
Intervention: County hospital care
Number of subjects: 0
Study 1873013 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous norepinephrine (NE) infusion
Number of subjects: 26
Study 1873013 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma NE levels
Number of subjects: 26
Study 6329613 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate, high-fiber diet (HCF)
Number of subjects: 20
Study 6329613 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 20
Study 31169550 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck-specific exercise (NSE)
Number of subjects: 216
Study 31169550 — intervention group
Group type: COMPARATOR
Intervention: Physical activity prescription
Number of subjects: 216
Study 28620894 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-trocar sleeve gastrectomy (experimental group)
Number of subjects: 90
Study 28620894 — intervention group
Group type: COMPARATOR
Intervention: Five-trocar technique (control group)
Number of subjects: 90
Study 28459237 — intervention group
Group type: EXPERIMENTAL
Intervention: Feiwei granules (FGs)
Number of subjects: 100
Study 28459237 — intervention group
Group type: COMPARATOR
Intervention: Jinshuibao capsules (JCs)
Number of subjects: 100
Study 25106092 — intervention group
Group type: EXPERIMENTAL
Intervention: High molecular weight barley β‐glucan (3 g)
Number of subjects: 23
Study 25106092 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight barley β‐glucan (3 g)
Number of subjects: 23
Study 25106092 — intervention group
Group type: COMPARATOR
Intervention: Control soup with no β‐glucan
Number of subjects: 23
Study 22071249 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-potency mOPV1
Number of subjects: 1002
Study 22071249 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-potency mOPV1
Number of subjects: 1002
Study 22071249 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal IPV (GlaxoSmithKline)
Number of subjects: 1002
Study 22071249 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular IPV (GlaxoSmithKline)
Number of subjects: 1002
Study 22071249 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular IPV (Panacea)
Number of subjects: 1002
Study 22071249 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal IPV
Number of subjects: 1002
Study 22071249 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular IPV
Number of subjects: 1002
Study 19671190 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin-naphthoquine combination (ANQ)
Number of subjects: 100
Study 19671190 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine plus single dose sulphadoxine-pyrimethamine (CQ+SP)
Number of subjects: 100
Study 17381474 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) and gonadotropin-releasing hormone agonist (GnRHa) treatment
Number of subjects: 30
Study 17381474 — intervention group
Group type: COMPARATOR
Intervention: No intervention (untreated)
Number of subjects: 30
Study 17381474 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treated and untreated groups
Number of subjects: 30
Study 17381474 — intervention group
Group type: EXPERIMENTAL
Intervention: GH/GnRHa treatment
Number of subjects: 30
Study 17381474 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treated and untreated participants
Number of subjects: 30
Study 15620935 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen-gentamicin (260 mg gentamicin) sponges applied within the sternotomy before wound closure
Number of subjects: 2000
Study 15620935 — intervention group
Group type: COMPARATOR
Intervention: Intravenous isoxazolyl-penicillin alone (control group)
Number of subjects: 2000
Study 12048335 — intervention group
Group type: EXPERIMENTAL
Intervention: All-out start strategy
Number of subjects: 8
Study 12048335 — intervention group
Group type: COMPARATOR
Intervention: Even pacing strategy
Number of subjects: 8
Study 10808388 — intervention group
Group type: EXPERIMENTAL
Intervention: HRCT score for whole lung
Number of subjects: 28
Study 10808388 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of lymphocytes HLA-DR in BAL from s.A
Number of subjects: 28
Study 10808388 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute number of CD25 in BAL from s.A
Number of subjects: 28
Study 10808388 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of lymphocytes in BAL from s.B
Number of subjects: 28
Study 10808388 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of HLA-DR lymphocytes in BAL from s.B
Number of subjects: 28
Study 8526828 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexedrine (10 mg)
Number of subjects: 6
Study 8526828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 8526828 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexedrine
Number of subjects: 6
Study 2191588 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 194
Study 2191588 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 194
Study 2191588 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (after initial monotherapy)
Number of subjects: 194
Study 6999546 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2-gel (0.25 mg)
Number of subjects: 100
Study 6999546 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2-gel (0.05 mg, 3 ml)
Number of subjects: 100
Study 6999546 — intervention group
Group type: COMPARATOR
Intervention: gel without PGE2
Number of subjects: 100
Study 31258082 — intervention group
Group type: EXPERIMENTAL
Intervention: Constipation (cases)
Number of subjects: 167
Study 31258082 — intervention group
Group type: COMPARATOR
Intervention: Control (no constipation)
Number of subjects: 167
Study 29766004 — intervention group
Group type: EXPERIMENTAL
Intervention: Zataria multiflora (ZM) extracts
Number of subjects: 30
Study 29766004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 26066587 — intervention group
Group type: EXPERIMENTAL
Intervention: High ascorbate group (HA) with plasma ascorbate levels >1 mmol/l
Number of subjects: 0
Study 26066587 — intervention group
Group type: COMPARATOR
Intervention: Low ascorbate group (LA) with plasma ascorbate levels <1 mmol/l
Number of subjects: 0
Study 25281045 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) via three 5-minute cycles of upper limb ischemia using a blood pressure cuff
Number of subjects: 62
Study 25281045 — intervention group
Group type: COMPARATOR
Intervention: Control (sham cuff)
Number of subjects: 62
Study 25281045 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 62
Study 23034095 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS) model with placement budgets of 25h, 40h, or 55h of job coach support.
Number of subjects: 100
Study 21028984 — intervention group
Group type: EXPERIMENTAL
Intervention: CHG-impregnated cloths applied thrice weekly
Number of subjects: 1562
Study 21028984 — intervention group
Group type: COMPARATOR
Intervention: Control cloths (Comfort Bath; Sage) applied thrice weekly
Number of subjects: 1562
Study 17998082 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported diabetes
Number of subjects: 430
Study 17998082 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported hypertension
Number of subjects: 430
Study 17998082 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported hypercholesterolemia
Number of subjects: 430
Study 17998082 — intervention group
Group type: COMPARATOR
Intervention: Self-reporting of diabetes among Surinamese vs. Dutch indigenous patients
Number of subjects: 430
Study 15204314 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 0
Study 15204314 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy diet
Number of subjects: 0
Study 15204314 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination low-fat/low-energy diet
Number of subjects: 0
Study 15204314 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 0
Study 11595689 — intervention group
Group type: EXPERIMENTAL
Intervention: Melanoma vaccine with gp100(280) peptide and tetanus helper peptide
Number of subjects: 22
Study 9678294 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogen 2.5 mg
Number of subjects: 11
Study 9678294 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogen 5 mg
Number of subjects: 11
Study 9678294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 8270757 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g added barley bran flour
Number of subjects: 79
Study 8270757 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g added barley oil extract
Number of subjects: 79
Study 8270757 — intervention group
Group type: COMPARATOR
Intervention: 20 g added cellulose (control)
Number of subjects: 79
Study 2683024 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS) chewable tablets at a dose of four tablets daily for 1 month
Number of subjects: 82
Study 2683024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 808195 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid infusion at 1.7 gm/kg
Number of subjects: 0
Study 808195 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid infusion at 1.0 gm/kg
Number of subjects: 0
Study 808195 — intervention group
Group type: COMPARATOR
Intervention: Dextrose infusion
Number of subjects: 0
Study 31618704 — intervention group
Group type: EXPERIMENTAL
Intervention: DPFC (cisplatin 40 mg/m2, docetaxel 40 mg/m2, 5-FU 2000 mg/m2, cetuximab 400/250 mg/m2)
Number of subjects: 180
Study 31618704 — intervention group
Group type: COMPARATOR
Intervention: PFC (cisplatin 100 mg/m2, 5-FU 1000 mg/m2, cetuximab 400/250 mg/m2)
Number of subjects: 180
Study 31618704 — intervention group
Group type: EXPERIMENTAL
Intervention: DPFC
Number of subjects: 180
Study 31618704 — intervention group
Group type: COMPARATOR
Intervention: PFC
Number of subjects: 180
Study 29025834 — intervention group
Group type: EXPERIMENTAL
Intervention: Orsiro stent with biodegradable polymer
Number of subjects: 2152
Study 29025834 — intervention group
Group type: COMPARATOR
Intervention: CX-ISAR stent (polymer-free)
Number of subjects: 2152
Study 29025834 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months DAPT duration
Number of subjects: 2152
Study 29025834 — intervention group
Group type: COMPARATOR
Intervention: 12 months DAPT duration
Number of subjects: 2152
Study 25218668 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (2000 mg/day by week 4, n = 38)
Number of subjects: 74
Study 25218668 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 36)
Number of subjects: 74
Study 25218668 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 74
Study 25218668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 24283058 — intervention group
Group type: COMPARATOR
Intervention: T+M (2g BID tinidazole for two days and vaginal suppositories of 1000 mg metronidazole at day 1 and 3)
Number of subjects: 539
Study 24283058 — intervention group
Group type: EXPERIMENTAL
Intervention: T+M+P (same as T+M plus topical administration of vaginal probiotic from day 5)
Number of subjects: 539
Study 24283058 — intervention group
Group type: COMPARATOR
Intervention: T+M
Number of subjects: 539
Study 24283058 — intervention group
Group type: EXPERIMENTAL
Intervention: T+M+P
Number of subjects: 539
Study 21534846 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation treatment
Number of subjects: 246
Study 19896572 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-item questionnaire
Number of subjects: 117
Study 19896572 — intervention group
Group type: COMPARATOR
Intervention: A/CS-12
Number of subjects: 117
Study 16825681 — intervention group
Group type: EXPERIMENTAL
Intervention: Palm oil
Number of subjects: 15